Acer Therapeutics Inc
ACER
ACER was delisted on the 8th of November, 2023.
28 hedge funds and large institutions have $2.22M invested in Acer Therapeutics Inc in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 2 closing their positions.
2,000% more call options, than puts
Call options by funds: $63K | Put options by funds: $3K
13% more capital invested
Capital invested by funds: $1.96M → $2.22M (+$262K)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
0% more funds holding
Funds holding: 28 → 28 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$42.8K |
| 2 |
CF
Copperwynd Financial
Scottsdale,
Arizona
|
+$33.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$15.3K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$14.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$64.4K |
| 2 |
Rockefeller Capital Management
New York
|
-$9K |
| 3 |
Goldman Sachs
New York
|
-$7.79K |
| 4 |
State Street
Boston,
Massachusetts
|
-$4.69K |
| 5 |
Renaissance Technologies
New York
|
-$3.04K |
ACER Hedge Fund Activity: Q3 2022 in Review
28 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Acer Therapeutics Inc (ACER) for Q3 2022, worth a combined $2.22M — up 13% from $1.96M a quarter earlier.
Fund positioning in ACER was balanced in Q3 2022: 2 funds opened new positions, 2 closed out, 9 added to existing stakes and 8 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $42.8K. The largest seller was Nantahala Capital Management, cutting an estimated $64.4K.
- 28 institutional investors held Acer Therapeutics Inc (ACER) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $2.22M of Acer Therapeutics Inc stock for Q3 2022, up 13% quarter-over-quarter.
- 2 funds opened new Acer Therapeutics Inc positions in Q3 2022 and 2 closed out, a net change of 0 holders.
- The largest Acer Therapeutics Inc buyer in Q3 2022 was Citadel Advisors, an estimated $42.8K added.
- The largest Acer Therapeutics Inc seller in Q3 2022 was Nantahala Capital Management, an estimated $64.4K sold.
Based on aggregated 13F filings for Q3 2022.